Retatrutide

Retatrutide is a peptide that activates GIP, GLP-1 and glucagon receptors, studied in human trials of obesity and type 2 diabetes.

Select strength

₹4,2001 vial

10 available

View COA for 20 mg

1 batch report available

Laboratory research only

Not for human or veterinary administration. Listed strength is a supplied specification; see the matching batch report for measured results.

Batch documentation

1 report is available for this strength. Match the batch number on your supplied material.

View available COAs

UNDERSTAND THE COMPOUND

What is Retatrutide?

Retatrutide combines activity at three hormone receptors involved in metabolic regulation. A 2023 phase 2 obesity trial enrolled 338 adults and measured weight change over 48 weeks; a separate phase 2 trial studied glucose control and weight in 281 adults with type 2 diabetes. Both used defined clinical study formulations under trial supervision. The obesity trial found greater weight reduction than placebo, alongside gastrointestinal adverse events and increases in heart rate. The diabetes study found that several, but not all, tested groups achieved greater HbA1c reductions than placebo.

Research context

Body-weight change in adults
HbA1c in type 2 diabetes
Tolerability and heart-rate changes

EXPLORE THE EVIDENCE

Studies & research references

Each source identifies what was studied and the limits of its findings. Published research is separate from this product’s batch COA.

Human trial · Randomised phase 2

Retatrutide for obesity: phase 2 trial (2023)

In 338 adults, retatrutide groups lost more weight than placebo over 48 weeks. Gastrointestinal adverse events were common; dose-related heart-rate increases were also reported.

Read study

Human trial · Randomised phase 2

Retatrutide in type 2 diabetes: phase 2 trial (2023)

This placebo- and dulaglutide-controlled study examined HbA1c, body weight and adverse events. All retatrutide groups except the lowest-dose group lowered HbA1c significantly more than placebo.

Read study

Documentation & selection

Which strengths are listed for Retatrutide?

Retatrutide is currently listed in 10 mg, 20 mg, 30 mg. Select a strength above to see its price, product image and current stock. Listed quantities are supplied specifications, not measured batch results.

Is a COA available for Retatrutide?

3 laboratory reports are published for this compound. Match the selected strength and available batch identifiers, and open the original document to check the actual test scope.

Check this compound’s reports How to verify a COA

What does this listing verify?

A catalogue listing is not a laboratory measurement. Check original documentation for the selected strength and batch before relying on identity, purity or quantity information.

Understand research evidence

Explore metabolic research Research & documentation Storage & handling Shipping Returns & refunds

Back to selection Back to all compounds